The ratings of major US investment banks are used to track the latest valuations and target prices on Wall Street daily, and to explore potential equity investment opportunities.

Risk warning:

Investing in small-cap stocks can be risky. Be prepared for potential challenges related to liquidity, high volatility, limited information, and financial instability. Always diversify your investments.

Today's key assessments and concerns

Canaccord Genuity: Maintaining a "buy" rating on AtaiBeckley ( AtaiBeckley Inc.(ATAI.US) ), while raising the price target from $15 to $17.

Truist Securities: Maintaining a "buy" rating on NUVATION BIO ( NUVATION BIO INC(NUVB.US) ), with a price target raised from $12 to $13.

BTIG: Maintaining a "buy" rating on Compass Pathways ( COMPASS Pathways Plc Sponsored ADR(CMPS.US) ), with a price target raised from $14 to $25.

Raymond James: Initial rating for SpaceX ( SpaceX(SPCX.US) ) stock at "Strong Buy", with a price target of $800.

Chardan Capital: Maintaining a "buy" rating on Metagenomi Therapeutics ( Metagenomi Therapeutics, Inc.(MGX.US) ), while lowering the price target from $7 to $5.

The symbol	Classification	Target price	Current price	Percentage of potential increase/decrease	(Classification) Agency
AtaiBeckley Inc.(ATAI.US)	to lift	$17.0	$5.19	227.55%	Canaccord Genuity
NUVATION BIO INC(NUVB.US)	to lift	$13.0	$5.67	129.28%	Truist Securities
COMPASS Pathways Plc Sponsored ADR(CMPS.US)	to lift	$25.0	$12.99	92.46%	BTIG
TeraWulf Inc.(WULF.US)	to lift	$33.0	$20.24	63.04%	Needham
Vera Therapeutics, Inc. Class A(VERA.US)	to lift	$70.0	$42.96	62.94%	B of A Securities
SpaceX(SPCX.US)	Initial classification	$800.0	$149.47	435.22%	Raymond James
Metagenomi Therapeutics, Inc.(MGX.US)	cut	$5.0	$1.32	278.79%	Chardan Capital
Largo Inc.(LGO.US)	cut	$2.4	$0.6652	260.79%	HC Wainwright & Co.
NUVATION BIO INC(NUVB.US)	cut	$19.0	$5.67	235.1%	RBC Capital
Verastem, Inc.(VSTM.US)	cut	$14.0	$4.85	188.66%	RBC Capital

comments:
Target price unit and current price: US Dollar;
Current price: As of the latest closing price of US stocks;
Potential percentage increase/potential decrease = (Agency target price - current price) / current price 100% (Current price = Last closing price up to the time of the count)

Lifting

Truist Securities: Maintaining a "Hold" rating on Amgen Amgen Inc.(AMGN.US) ) stock, while raising the price target from $327 to $340.

Oppenheimer: Maintaining an "outperform" rating for Corning ( Corning Inc(GLW.US) ), while raising the price target from $210 to $230.

JP Morgan: Maintaining an "overweight" rating on Eli Lilly ( Eli Lilly and Company(LLY.US) ), while raising the price target from $1,300 to $1,400.

Jefferies: Maintaining a "hold" rating on Rivian Automotive Rivian Automotive(RIVN.US) ) stock, while raising the price target from $16 to $17.

RBC Capital: Maintaining its "outperform" rating for Tesla ( Tesla Motors, Inc.(TSLA.US) ) stock, while raising its price target from $475 to $500.

First Coverage

Morgan Stanley: Initial rating for Kingsoft Cloud ( Kingsoft Cloud Holdings(KC.US) ) at "overweight", with a target price of $15.

Goldman Sachs: Initial rating for SpaceX ( SpaceX(SPCX.US) ) stock at "buy", with a target price of $205.

Barclays: Initial rating for Welltower ( Welltower, Inc.(WELL.US) ) at "market-like weight", with a price target of $254.

reduction

Mizuho: Maintaining its "outperform" rating for ConocoPhillips ConocoPhillips(COP.US) ), while lowering its price target from $150 to $146.

Citigroup: Maintaining a "neutral" rating on Domino's Domino's Pizza, Inc.(DPZ.US) ) stock, while lowering its price target from $365 to $335.

UBS: Maintaining a "buy" rating on Wells Fargo ( Wells Fargo & Company(WFC.US) ), while lowering the price target from $105 to $104.

Editor's Note: This content was created by Saham's AI-powered SaaS tool and reviewed by our editorial team.
Risk Warning: Investing involves risk. Securities may rise, fall, or become worthless. Investing does not guarantee profits and may result in losses. Past performance is not necessarily indicative of future results. Before making any investment decision, investors should assess their financial situation, investment objectives, experience, risk tolerance, and understand the nature of the investment products and their associated risks. For more details on the nature and risks of each investment product, please read the relevant offering documents carefully. If you have any questions, it is advisable to seek independent professional advice.